Recently, Shandong Wohua Pharmaceutical Co.Ltd(002107) and the second hospital of Shandong University jointly completed the “construction and application of cardiac rehabilitation system after acute myocardial infarction intervention” project, which won the second prize of Shandong science and technology progress award.
It is reported that this technology takes the quality control method and pharmacodynamic effect of Xinkeshu tablet as the starting point, optimizes the treatment indications and medication scheme of Xinkeshu tablet combined with western medicine in cardiac rehabilitation after interventional surgery for acute myocardial infarction, and effectively improves the quality control level of the product. At the same time, the study also shows that Xinkeshu tablet can significantly improve the chest tightness, palpitation symptoms and combined anxiety and depression of some patients after acute myocardial infarction intervention.
The company said that Xinkeshu tablet is one of the Shandong Wohua Pharmaceutical Co.Ltd(002107) four exclusive medical insurance pillar products. It is a pure plant formula and conforms to the ABCDE principle of secondary prevention and treatment of cardiovascular diseases. With its unique therapeutic effect, Xinkeshu tablet has a large market share and academic brand influence nationwide. According to the statistics from MI nei.com, in the first half of 2021, Chinese urban public, urban community, county-level public and township public health ranked second among the oral tablets of Chinese patent medicines for cardiovascular and cerebrovascular diseases. At the same time, in the 2021 edition of the national medical insurance drug catalogue published on December 3, 2021, the product is changed from medical insurance class B to medical insurance class A, which shows that its efficacy and quality are continuously recognized, which will also reduce the economic burden of long-term medication and improve the quality of life of patients.
Xinkeshu tablet focuses on the “double heart effect”, which can not only improve the common clinical symptoms of patients with cardiovascular diseases such as chest tightness, chest pain, palpitation and shortness of breath, but also improve the bad mood of patients with cardiovascular diseases. It has been successively included in 17 paths, guidelines and consensus, published more than 400 academic papers, 10 national invention patents, and won the support of “863” plan, major new drug creation projects and other projects, It has won the second prize of national science and technology progress award, cutting-edge brand in China pharmaceutical brand list, people’s reassuring medicine and many other honors. It has been highly praised by patients and the market for more than 40 years.
In recent years, in terms of joint research and development, Shandong Wohua Pharmaceutical Co.Ltd(002107) has carried out industry university research cooperation with many Chinese scientific research institutions, such as the Chinese Academy of traditional Chinese medicine, Shandong University, Tianjin University of traditional Chinese medicine, Shandong University of traditional Chinese medicine and so on. Make full use of the advantages of R & D resources of scientific research institutions, carry out the joint development of key technologies, effectively integrate talents, funds and information resources, and promote the transformation of scientific and technological achievements and the research and application of key technologies. It has undertaken major scientific and technological projects of “major new drug creation”, national key R & D plan, national traditional Chinese medicine standardization construction project, Shandong provincial scientific development plan, Shandong Provincial independent innovation and achievement transformation project, Shandong provincial key R & D plan and other key topics.
Relevant data show that after 2030, China’s population aged 65 and over may account for more than 20% of the total population. With the increasing aging of the population, the prevalence of chronic diseases in the middle-aged and elderly, represented by cardiovascular and cerebrovascular diseases, will continue to rise, and the demand for related medicine will also continue to grow Shandong Wohua Pharmaceutical Co.Ltd(002107) relying on superior products such as Xinkeshu tablets, we have built a four in one technical system of “R & D – process – quality control – clinical” of cardio cerebrovascular Chinese patent medicine, systematically improve product quality, deeply tap clinical value, and better meet the needs of patients and the market with excellent curative effect and kind quality.
